Search

for
Search:

Sort by

Research

90-120 / 1000+ results

Discovery of Clinically Approved Drugs Capable of Inhibiting SARS-CoV-2 In Vitro Infection Using a Phenotypic Screening Strategy and Network-Analysis to Predict Their Potential to Treat COVID-19

research Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19

13 citations , July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)”

Four drugs were found that could potentially treat COVID-19 by inhibiting the virus in lab tests.

research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods

42 citations , April 2021 in “Pharmaceuticals”

Five FDA-approved drugs may help block COVID-19 virus entry.

research Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity

8 citations , May 2022 in “Journal of medicine and life”

COVID-19 patients may experience hair loss, but it's not linked to their age or sex.

Aftermath of COVID-19 Through the Eyes of Trichoscopy

research After Math of COVID Through Eyes of Tricoscopy

August 2024

COVID-19 can cause significant hair loss.

research Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures

August 2018 in “bioRxiv (Cold Spring Harbor Laboratory)”

Existing drugs, including a blood pressure medication, show promise as new treatments for influenza.

research Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles

20 citations , July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)”

Six existing drugs may help block virus entry in COVID-19.

5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double-Blind Placebo-Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

research 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men

5 citations , November 2020 in “medRxiv (Cold Spring Harbor Laboratory)”

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

Drug Interactions Between Common Dermatological Medications and the Oral Anti-Covid-19 Agents Nirmatrelvir-Ritonavir and Molnupiravir

research Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir

5 citations , December 2022 in “Annals Academy of Medicine Singapore”

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

A Microscopy-Based Small Molecule Screen in Primary Neurons Reveals Neuroprotective Properties of the FDA-Approved Anti-Viral Drug Elvitegravir

research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir

3 citations , September 2020 in “Molecular Brain”

The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.

research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders

45 citations , July 2025 in “Journal of Medicinal Chemistry”

The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.

research The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients

6 citations , March 2023 in “Frontiers in Cellular and Infection Microbiology”

Golvatinib shows promise as a treatment for Omicron in elderly patients.

research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis

16 citations , April 2014 in “Expert Opinion on Pharmacotherapy”

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

41 citations , February 2021 in “Cureus”

Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.

Hydroxychloroquine, Nitazoxanide, and Ivermectin Have Similar Effects in Early COVID-19: A Head-to-Head Comparison of the Pre-AndroCoV Trial

research Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial.

4 citations , October 2020 in “Research Square (Research Square)”

Hydroxychloroquine, nitazoxanide, and ivermectin were similarly effective in treating early COVID-19.

research New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))

January 2022 in “Drugs of Today”

research A systematic review on Drug Re-profiling/Re-Purposing

August 2022 in “IARS international research journal”

The document concludes that drug repurposing, which is reusing known medicines for new illnesses, can provide faster, cheaper treatment options for various serious diseases, including cancer, COVID-19, and rare diseases.

research Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main Protease

8 citations , April 2020

The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.

research Anticoronavirus Isoquinoline Alkaloids: Unraveling the Secrets of Their Structure–Activity Relationship

October 2025 in “Influenza and Other Respiratory Viruses”

Certain alkaloids could help create new coronavirus drugs.

research Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay

111 citations , February 2017 in “Antiviral research”

Researchers found several compounds that could potentially treat Zika virus.

research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)

2 citations , September 2022 in “Annals of Oncology”

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin, or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

research Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.

16 citations , November 2020 in “Research Square (Research Square)”

Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.

research Development of Provesicular Nanodelivery System of Curcumin as a Safe and Effective Antiviral Agent: Statistical Optimization, In Vitro Characterization, and Antiviral Effectiveness

37 citations , December 2020 in “Molecules”

A new delivery system makes Curcumin more effective and safer against viruses.

research A Reappraisal of the Antiviral Properties of and Immune Regulation through Dietary Phytochemicals

11 citations , October 2023 in “ACS Pharmacology & Translational Science”

Plant compounds may boost antiviral treatments.

research Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

11 citations , November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)”

Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.

A Skin Organoid-Based Infection Platform Identifies an Inhibitor Specific for Hand, Foot, and Mouth Disease

research A skin organoid-based infection platform identifies an inhibitor specific for HFMD

March 2025 in “Nature Communications”

NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.

research [Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].

5 citations , December 2015 in “PubMed”

Some gonadal hormone drugs can block filovirus entry into cells.

research Cepharanthine Suppresses Herpes Simplex Virus Type 1 Replication Through the Downregulation of the PI3K/Akt and p38 MAPK Signaling Pathways

30 citations , December 2021 in “Frontiers in Microbiology”

Cepharanthine effectively reduces Herpes Simplex Virus Type 1 by blocking certain cell pathways and promoting cell death.

research Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase

18 citations , August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)”

Two existing drugs may help treat COVID-19 by inhibiting a key viral protein.

research HHV-6A and HHV-6B in Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms

2 citations , January 2014 in “Elsevier eBooks”

The document concludes that reactivation of herpesviruses, especially HHV-6, is linked to severe symptoms and complications in drug-induced hypersensitivity syndrome.

research Fármacos de uso frecuente en dermatología como terapia para COVID-19

4 citations , October 2020 in “Actas Dermo-Sifiliográficas”

Common dermatology drugs were considered but are controversial for COVID-19 treatment.

← Previous page Next page →